Boehringer Ingelheim (BI) and Synaffix, an Oss, the Netherlands-based antibody drug conjugate (ADC) technology company and a subsidiary of Lonza, have formed an agreement under which BI has licensed Synaffix’s ADC technology, in a deal worth up to $1.3 billion. Synaffix’s technology platform includes payload and site-specific linker technologies, Lonza acquired Synafixx in 2023.  

Synaffix has developed a clinically validated ADC platform technology that uses an enzymatic modification of native glycan anchor points on antibodies to enable the development of ADCs and bispecifics. BI plans to apply the technology to address tumor targets from its portfolio to develop cancer treatments. 

Under the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated upon signature of the deal, and additional targets will subsequently be nominated within a predefined timeframe. In addition to the upfront payment, Synaffix is eligible to receive potential additional milestone payments of up to $1.3 billion, plus additional royalty payments on net sales of resulting products. 

Source: Boehringer Ingelheim